Abstract
AbstractRS-82856 is a new inotropic agent for treatment of congestive heart failure. Oral bioavailability was found to be very poor likely due to insufficient aqueous solubility (∼ 4.4 mcg/ml) and slow dissolution rate. Inclusion complexes with cyclodextrins were shown to enhance the solubility, dissolution rate and thereby oral bioavailability of the drug. Maximum solubilities of the drug complexes with alpha-, beta-, and gamma-cyclodextrin were 14, 30 and 55 times, respectively, more soluble than the uncomplexed drug. Phase solubility studies revealed a 1:l complexation constant of 136.5, 370.4, and 64.7 for alpha -, beta - and gamma-cyclodextrin complexes, respectively. The complexation between beta-cyclodextrin and the drug is apparently the strongest among the three cyclodextrins. Dissolution profiles of the beta-cyclodextrin complex indicated a dramatic increase in dissolution rate compared to that of the drug. However,a physical mixture of the beta-cyclodextrin and the drug gave an identical dissol...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
